Adachi Takanori, Nakamura Mitsuhiro, Shintani Takashi, Mitsuyoshi Takamasa, Kakino Ryo, Ogata Takashi, Ono Tomohiro, Tanabe Hiroaki, Kokubo Masaki, Sakamoto Takashi, Matsuo Yukinori, Mizowaki Takashi
Division of Medical Physics, Department of Information Technology and Medical Engineering, Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Med Phys. 2021 Apr;48(4):1781-1791. doi: 10.1002/mp.14769. Epub 2021 Mar 2.
To predict radiation pneumonitis (RP) grade 2 or worse after lung stereotactic body radiation therapy (SBRT) using dose-based radiomic (dosiomic) features.
This multi-institutional study included 247 early-stage nonsmall cell lung cancer patients who underwent SBRT with a prescribed dose of 48-70 Gy at an isocenter between June 2009 and March 2016. Ten dose-volume indices (DVIs) were used, including the mean lung dose, internal target volume size, and percentage of entire lung excluding the internal target volume receiving greater than x Gy (x = 5, 10, 15, 20, 25, 30, 35, and 40). A total of 6,808 dose-segmented dosiomic features, such as shape, first order, and texture features, were extracted from the dose distribution. Patients were randomly partitioned into two groups: model training (70%) and test datasets (30%) over 100 times. Dosiomic features were converted to z-scores (standardized values) with a mean of zero and a standard deviation (SD) of one to put different variables on the same scale. The feature dimension was reduced using the following methods: interfeature correlation based on Spearman's correlation coefficients and feature importance based on a light gradient boosting machine (LightGBM) feature selection function. Three different models were developed using LightGBM as follows: (a) a model with ten DVIs (DVI model), (b) a model with the selected dosiomic features (dosiomic model), and (c) a model with ten DVIs and selected dosiomic features (hybrid model). Suitable hyperparameters were determined by searching the largest average area under the curve (AUC) value in the receiver operating characteristic curve (ROC-AUC) via stratified fivefold cross-validation. Each of the final three models with the closest the ROC-AUC value to the average ROC-AUC value was applied to the test datasets. The classification performance was evaluated by calculating the ROC-AUC, AUC in the precision-recall curve (PR-AUC), accuracy, precision, recall, and f1-score. The entire process was repeated 100 times with randomization, and 100 individual models were developed for each of the three models. Then the mean value and SD for the 100 random iterations were calculated for each performance metric.
Thirty-seven (15.0%) patients developed RP after SBRT. The ROC-AUC and PR-AUC values in the DVI, dosiomic, and hybrid models were 0.660 ± 0.054 and 0.272 ± 0.052, 0.837 ± 0.054 and 0.510 ± 0.115, and 0.846 ± 0.049 and 0.531 ± 0.116, respectively. For each performance metric, the dosiomic and hybrid models outperformed the DVI models (P < 0.05). Texture-based dosiomic feature was confirmed as an effective indicator for predicting RP.
Our dose-segmented dosiomic approach improved the prediction of the incidence of RP after SBRT.
使用基于剂量的放射组学(剂量组学)特征预测肺部立体定向体部放疗(SBRT)后2级或更严重的放射性肺炎(RP)。
这项多机构研究纳入了247例早期非小细胞肺癌患者,这些患者在2009年6月至2016年3月期间在等中心接受了48 - 70 Gy的处方剂量SBRT。使用了10个剂量体积指数(DVI),包括平均肺剂量、内靶区体积大小以及接受大于x Gy(x = 5、10、15、20、25、30、35和40)的全肺(不包括内靶区体积)百分比。从剂量分布中提取了总共6808个剂量分割的剂量组学特征,如形状、一阶和纹理特征。患者被随机分为两组:模型训练组(70%)和测试数据集(30%),共进行100次。剂量组学特征被转换为z分数(标准化值),均值为零,标准差(SD)为1,以使不同变量处于同一尺度。使用以下方法降低特征维度:基于斯皮尔曼相关系数的特征间相关性和基于轻梯度提升机(LightGBM)特征选择函数的特征重要性。使用LightGBM开发了三种不同的模型如下:(a)一个包含10个DVI的模型(DVI模型),(b)一个包含选定剂量组学特征的模型(剂量组学模型),以及(c)一个包含10个DVI和选定剂量组学特征的模型(混合模型)。通过在接受者操作特征曲线(ROC - AUC)中搜索分层五折交叉验证下最大的曲线下平均面积(AUC)值来确定合适的超参数。将最终三个模型中ROC - AUC值最接近平均ROC - AUC值的每个模型应用于测试数据集。通过计算ROC - AUC、精确召回率曲线中的AUC(PR - AUC)、准确性、精确率、召回率和F1分数来评估分类性能。整个过程通过随机化重复100次,为三种模型中的每一种开发100个单独的模型。然后为每个性能指标计算100次随机迭代的平均值和SD。
37例(15.0%)患者在SBRT后发生RP。DVI模型、剂量组学模型和混合模型中的ROC - AUC值和PR - AUC值分别为0.660±0.054和0.272±0.052、0.837±0.054和0.510±0.115、0.846±0.049和0.531±0.116。对于每个性能指标,剂量组学模型和混合模型均优于DVI模型(P < 0.05)。基于纹理的剂量组学特征被确认为预测RP的有效指标。
我们的剂量分割剂量组学方法改善了SBRT后RP发生率的预测。